MCItect: Clinical trial data

Data from 157 patients in a U.S. and European calibration study showed that MCItect had 75% total prediction accuracy for detecting patients converting to AD within 2 years, with 75% sensitivity and 73% specificity. MCItect achieved 88% total accuracy amongst patients with >=1 apolipoprotein E (APOE) allele (n=25). DiaGenic said a validation study with MCItect will require a strategic partnership or additional funding. ...